Highlights Transgene

Equities

TNG

FR0005175080

Real-time Euronext Paris Other stock markets 10:22:25 2024-05-17 am EDT			5-day change	1st Jan Change
1.334 ^EUR	+0.45%		-1.04%	-2.63%

Apr. 10	Transgene: presents vaccine results at AACR	CF
Mar. 28	Transgene CFO Steps Down; Successor Assumes Office	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transgene: presents vaccine results at AACR	Apr. 10	CF
Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	Mar. 12	MT
Transgene, NEC Corporation and BostonGene Corporation Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	Mar. 05	CI
UniQure Says US FDA Clears Investigational New Drug Application for Fabry Disease Candidate	Nov. 29	MT
Transgene and BioInvent International AB Announces First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA	23-10-10	CI
Transgene SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Transgene Obtains $15 Million from Sale of Minority Stake in Chinese Biopharmaceutical Group	23-07-18	MT
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023	23-06-06	CI
BioInvent Ready for Combination Studies with BT-001	23-06-05	CI
Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023	23-06-05	CI
Oxford Nanopore, PathoQuest Partner to Develop New Testing Service for Biopharma Sector	23-05-12	MT
AstraZeneca Ends Oncolytic Virus R&D Partnership with Transgene	23-05-05	MT
4D Molecular Therapeutics Acquires Complement Pathway Inhibitor Payload for 4D-175 to Treat Geographic Atrophy	23-04-24	MT
Transgene SA and NEC Corporation Announces New Data Showing That Transgene and Nec's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses Against Tumors Presented at AACR 2023	23-04-18	CI
Transgene Presents Preclinical Results Showing TG6050	23-04-17	CI
Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-16	CI
Transgene Gets French Nod To Launch Early-stage Trial For Non-small Cell Lung Cancer Drug	23-01-06	MT
Transgene Receives Approval to Start a Phase I Trial of TG6050	23-01-06	CI
Transgene Discloses Positive Interim Analysis Results of Phase 2 Trial of TG4001, Avelumab to Treat Anogenital Cancers	22-11-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Transgene

Equities

TNG

FR0005175080

Highlights

Filters